@AASLDtweets clearly it is time for the curtain to close on #emricasan at least in liver disease... #LiverMtg19

@AASLDtweets dr. Harrison: #emricasan doesn’t meet fibrosis primary endpoint in NASH (nor any other endpoints) #LiverMtg19

@EASLedu apoptosis inh. incl. #selonsertib being tested for alcoholic hepatitis. #emricasan abandoned due to incr. exposure #ilc2017

@EASLedu Prof. Peck: caspase inhibitor #emricasan theoretical role in preventing HCC in patients at risk. Also potential risks. #ILC2016

Late breaker: ELAD on life support, #sofosbuvir #velpatasvir pangenotypic cure for (almost) all. #emricasan promising #Liver15 #liverleader

Dr. Garcia-Tsao: 28d PO #emricasan reduces severe portal HTN in small group of compensated cirrhotics. ALT lower. #Liver15 #LiverLeader

Can Oral Pan-caspase inh. lower portal HTN? #emricasan data in compensated cirrhosis to be presented #latebreaker #liver15 #LiverLeader

marketwatch.com

#Conatus to share pre-clinical data on caspase inhibitor #emricasan in bile duct ligation model at #liver15 $CNAT http://on.mktw.net/1jB41Jl

Conatus Announces Initial Baseline Data From Phase 2b POLT-#HCV SVR Clinical Trial of #Emricasan https://shar.es/1qqzYv